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Summary
Long-chain acyl-CoA synthetases (ACSL) activate fatty acids (FA) and provide substrates for
virtually every metabolic pathway that catabolizes FA or synthesizes complex lipids. We have
hypothesized that each of the five cloned ACSL isoforms partitions FA towards specific downstream
pathways. Adult heart expresses all five cloned ACSL isoforms, but their independent functional
roles have not been elucidated. Studies implicate ACSL1 in both oxidative and lipid synthetic
pathways. To clarify the functional role of ACSL1 and the other ACSL isoforms (3–6), we examined
ACS specific activity and Acsl mRNA expression in the developing mouse heart which increases FA
oxidative pathways for energy production after birth. Compared to the embryonic heart, ACS specific
activity was 14-fold higher on post-natal day 1 (P1). On P1, as compared to the fetus, only Acsl1
mRNA increased, whereas transcripts for the other Acsl isoforms remained the same, suggesting that
ACSL1 is the major isoform responsible for activating long-chain FA for myocardial oxidation after
birth. In contrast, the mRNA abundance of Acsl3 was highest on E16, and decreased dramatically
by P7, suggesting that ACSL3 may play a critical role during the development of the fetal heart. Our
data support the hypothesis that each ACSL has a specific role in the channeling of FA towards
distinct metabolic fates.
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For the mouse fetus the primary energy source is maternally –supplied glucose, but after birth
the energy source shifts abruptly from carbohydrate to lipid when 70 percent of the calories
ingested by the suckling pup come from milk triacylglycerol [1]. During the third week of life
the pup begins to nibble increasing amounts of chow, and after weaning the mouse again eats
a diet that is about 60% carbohydrate and less than 14% fat. Fuel use by the developing rodent
heart depends on lactate and glucose in the fetus, and on oxidative metabolism of glucose and
glycogen immediately after birth [2]. By 1 week of age, however, the heart derives more than
70% of its energy from the oxidation of fatty acids [2–4] and this preferred use of fatty acids
for energy persists throughout life [5].
The postnatal dependence of the heart on fatty acid as its primary energy source is aided by
rapid postnatal increases in the activities of enzymes required for β-oxidation, including
MCAD, LCAD, M-CPT1, and ACO [6–10]. These increases in activity are controlled by up-
regulation of gene transcription [10,11].
The use of fatty acids for oxidation depends on their initial activation by long chain acyl-CoA
synthetases (ACSLs) which catalyze the conversion of long chain fatty acids to long chain fatty
acyl-CoAs. ACSL activity is thus an integral initial step for virtually every metabolic pathway
that degrades fatty acids or synthesizes complex lipids [11–13]. The formation of acyl-CoAs
occurs in a two step process. The first step converts free fatty acid to an acyl-AMP intermediate
through the pyrophosphorolysis of ATP. In the second step the thiol group of CoA displaces
AMP to form acyl-CoA [14]. Acyl-CoAs then enter metabolic pathways, including β-
oxidation, fatty acid retroconversion, desaturation, and elongation, glycerolipid synthesis,
phospholipid reacylation, cholesterol ester synthesis, and wax ester formation. Acyl-CoAs also
activate numerous cell processes and act as signaling molecules [12,13,15–18].
Five ACSL isoforms have been cloned in humans and rodents. ACSL1, 5, and 6 share over
60% amino acid identity [19]. ACSL3 and 4 have 68% identity with each other and
approximately 30 percent homology with ACSL1 [20]. The ACSL isoforms differ in their
tissue distribution, organelle location, relative expression, enzyme kinetics, regulation, and
substrate preferences [12,13,21,22]. Most ACSL isoforms are intrinsic membrane proteins, but
several have secondary start sites that cleave the transmembrane domain and render the enzyme
membrane associated [23].
Most tissues express more than one ACSL isoform [24], and we have hypothesized that the
individual ACSL isoforms each channel fatty acids toward distinct metabolic fates. The
developmental expression and role of individual ACSL isoforms in the heart is not known. All
five ACSL isoforms are expressed in mouse and rat heart, with Acsl1 having the most abundant
transcripts [24,25]. Expression of Acsl1 is low in liver and heart from mice lacking PPARα
[26,27], a transcription factor which directs the program of fatty acid oxidation [28].
Myocardial contraction is poor in PPARα−/− mice both under basal conditions and after beta1
adrenergic stimulation, and the heart becomes fibrotic [29]. In addition, oleate and PPARα
agonists increase Acsl1 expression in cultured rat cardiomyocytes [25]. These data suggest that
ACSL1 might provide FA destined for oxidation. In contrast, fasting or a high-fat diet does
not increase Acsl1 expression [25]. However, heart specific overexpression of ACSL1 results
in excess myocardial TAG accumulation [30], suggesting that ACSL1 channels FA towards
esterification.
In order to clarify the normal functional role of ACSL1 and the ACSL isoforms 3–6 in heart,
we examined mRNA expression and activities in developing mouse heart. Because the fuel
sources and heart requirements for energy substrates change dramatically from embryo to adult,
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we hypothesized that characterizing ACSL expression and activity during heart development
would allow us to better understand the function of the individual ACSL isoforms.
Materials and Methods
Animals
C57BL/6J mice were obtained from Jackson Laboratories. Mice were housed on a 12-h/12-h
light/dark cycle with free access to water and Prolab RMH 3000 SP76 rodent diet. Pregnancies
were timed by single night mating and visualization of a vaginal plug. Litter sizes were
maintained at 5–6 pups per litter. Pups were weaned on postnatal day 21 and then housed in
groups of 4. All experiments were conducted in accordance with protocols approved by the
University of North Carolina Institutional Animal Care and Use Committee.
Tissue Extraction
Mice were anesthetized by halothane inhalation. Hearts and brains were excised on embryonic
day 16 (E16), and on postnatal days 1, 7, 18, and 25. Adult mice were sacrificed at 2 months.
Mouse hearts were removed and immediately placed in RNALater (Qiagen) or snap frozen in
liquid nitrogen.
Total Membrane Isolation
On ice, hearts were resuspended in 1 ml of Medium I (10 mM Tris HCl, pH 7.4, 0.25 M sucrose)
plus 1 mM dithiothreitol (DTT) and protease inhibitors (33.3 μM 4-(2-Aminoethyl)-
bezenesulfonylfluoride (AEBSF), 1.033 mM EDTA, 4.3 μM bestain, 0.5 μM E-64, 33.3 μM
leupeptin, 33.3 μM aprotinin) (Protease Inhibitor Cocktail for general use, Sigma). Tissue was
homogenized on ice with a motor-driven Teflon-glass homogenizer for 15 up-and-down
strokes. The homogenate was centrifuged at 1000 x g for 10 min at 5ºC and the supernatant
was placed in a new ultracentrifuge tube. The pellet was resuspended in 1 ml of Medium I plus
1 mM DTT and recentrifuged at 1000 x g for 10 min. The resulting supernatant was added to
the previous supernatant, and a total membrane fraction was collected by centrifugation at
100,000 x g for 3 h. The membrane pellet was resuspended in 200 μl of Medium I plus 1 mM
DTT and homogenized on ice. Protein concentration was determined using the Bicinchonic
Acid method (Pierce) using bovine serum albumin (BSA) as the protein standard. The
membrane fraction was stored in aliquots at −80°C.
Assay for ACSL activity
The acyl-CoA synthetase assay contained 50 μM [14C]palmitate in 0.5 mM Triton X-100, 1
μM EDTA, 5 mM ATP, 250 μM CoA, 175 mM Tris HCl, pH 7.4, 8 mM MgCl2, and 5 mM
DTT in a total volume of 200 μl. In some assays, varying concentrations of unlabeled
arachidonate were added to the assay as a competitor. Triacsin C (10 μM in DMSO) or
troglitazone (50 μM in DMSO) was added directly to the enzyme reaction mixture during
inhibition assays. DMSO alone does not inhibit ACSL activity [31]. For heart samples from
postnatal days 1, 7, 18, and 25, the assay was initiated with 2 to 6 μg protein and ACS specific
activity was measured after a 5 min incubation with substrates at 37 C. Assays of ACS activity
in adult heart contained 1 to 3 μg protein. Because ACS activity was very low at E16, 2 to 6
μg protein was incubated with substrates for 10 min. The reaction was stopped with 2-
propanol:heptane:1 M sulfuric acid (80:20:1) and the acyl-CoA products were extracted from
heptane with water. Specific activities were proportional with time for 15 min and with protein
to 10 μg, allowing measurement of initial rates.
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The abundance of the ACSL mRNA transcripts was determined by quantitative real-time (qRT)
PCR. DNA-free total RNA was isolated from tissue with RNeasy Fibrous Tissue Mini Kit
(Qiagen). RNA was checked for purity by determining that the A260:A280 ratio was
approximately 1.85. 20 ng of RNA and 20 μl of reaction buffer (0.05 μg forward primer, 0.05
μg reverse primer, 20 μM family probe, 5 units reverse transcriptase (Invitrogen), 15 μl
Universal PCR MasterMix (Applied Biosystems). Quadruplicate reactions were run for all
samples. qRT-PCR was run on an ABI Prism 7700 Sequence Detection System using a
TaqMan® PCR protocol (48 ºC for 30 min, 95 ºC 10 min, 95 ºC 15 sec, 60 ºC 1 min for 40
cycles). Primers and probes for QRT-PCR are listed in Table 1. All probes were dual labeled
with FAM (6-carboxyfluorescein) as reporter and TAMRA (6-carboxytetramethylrhodamine)
as quencher. The ACSL primers were designed to amplify all splice variants [24]. PCR
efficiency was calculated from amplification plots [32] and expression of transcripts is
presented as a ratio to the level of GAPDH (endogenous control) and relative expression to
E16 was determined by REST-MCS [33,34]. ACSL abundance as a percent of total ACSL
transcripts was determined by taking the inverse of the PCR efficiency raised to the delta Ct
for each isoform and time point, adding the total for each time point and calculating % of total.
Extraction and measurement of fatty acids
Hearts were homogenized in water and lipids were extracted by the 2-step Bligh-Dyer method
[35]. The lower (chloroform) phase was transferred to a clean tube and evaporated to dryness
under nitrogen. The residual lipids were saponified and the fatty acids trans-methylated by
sequential 1 ml additions of 4.25% NaOH in CHCl3:MeOH (2:1, v/v) and 1N HCl in saline
[36]. Samples were mixed vigorously and then centrifuged at 1500 x g for 5 min. The lower
phase containing the fatty acid methyl esters was transferred to a clean, dry tube and evaporated
to dryness under nitrogen. Fatty acid methyl esters were then resuspended in 50 μl undecane,
and analyzed using capillary gas chromatography (GC). Fatty acid methyl esters were analyzed
by Fast GC on a Perkin Elmer AutoSystem XL Gas Chromatograph (Shelton, CT), split
injection, with helium as the carrier gas. The methyl esters were separated on a capillary column
coated with 70% cyanopropyl polysilphenylene – siloxane (10 m x 0.1 mm ID- BPX70 0.2
μm; SGE, Austin, TX); injector 240ºC and detector 280ºC. Data were analyzed with the Perkin
Elmer Totalchrom Chromatography Software, version 6.2. Heptadecanoic acid (17:0) was
added to the samples as an internal standard to correct for recovery and quantitation. Individual
fatty acids were identified by comparing their retention with authentic standards (Nu Chek
Prep, Elysian, MN). The fatty acid analysis was performed by the Biochemistry Core of the
University of North Carolina Clinical Nutrition Research Unit.
Results
Heart ACS specific activity increases 14-fold after birth
The fetal heart utilizes glucose primarily, whereas fatty acids derived from milk triacylglycerol
become the major fuel after birth. Thus, we expected heart ACSL activity to increase
immediately after birth. As reported in rat heart, [37], ACSL specific activity measured with
[14C]palmitate as substrate was very low on E16 (1.3 nmol/min/mg). In contrast, on P1, mouse
heart ACSL specific activity increased 14-fold to19 nmol/min/mg (Fig. 1). These results are
consistent with postnatal up-regulation of a program of fatty acid oxidation. ACSL specific
activity remained unchanged through postnatal day 25, although with heart growth, total heart
ACSL activity increased 6.3-fold. In the adult mouse heart, ACSL specific activity was 6.6-
fold higher (125 nmol/min/mg) than that measured in the neonate and 90-fold higher than
present at E16.
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Heart ACSL1 mRNA abundance increases after birth
To determine which ACSL isoforms are present in the fetus and which contribute to the
postnatal increase in ACS activity, we analyzed the abundance of each of the five Acsl mRNA
transcripts. Only the transcript levels for Acsl1 increased after birth (Fig. 2A). The ratio of
Acsl1 to Gapdh was 4-fold higher on P1 than on E16 and reached a maximum on P18 at 6-fold
higher than E16. The abundance of Acsl1 transcripts was similar to the observed developmental
increase in mRNA level of the fatty acid oxidative enzymes MCAD and ACO (Fig. 2C, D),
suggesting that Acsl1 message is up-regulated postnatally with the fatty acid oxidation
program. As a percent of total Acsl transcripts, the abundance of Acsl1 message rose from 7.5%
of total on E16 to 21% on P1 and to 50% on P18 through adult (Fig. 3). The ontological pattern
observed for Acsl1 message from E16 to P25 mirrors the developmental increase observed
with ACSL activity shown in Fig. 1. Taken together, these data suggest that ACSL1 is the
primary isoform in the heart that activates long-chain fatty acids for oxidation.
The change in abundance of Acsl3 was the inverse of that observed for Acsl1. The ratio of
Acsl3 to Gapdh was highest on E16 and P1 and decreased 70% by P7 (Fig. 2 B). Acsl3 mRNA
abundance continued to diminish throughout the neonatal period and was lowest in the adult.
Acsl3 message comprised 40% of total Acsl transcripts on E16 and P1, dropped to 12% of total
on P7, and only represented 3.5% of transcripts in the adult (Fig. 3). Unlike Acsl1 and 3, the
abundance of Acsl4 and 5 mRNA did not change from embryo to neonate to adult (data not
shown). Acsl6 mRNA was virtually undetectable until P25 when the percent of Acsl6 rose to
1% of total transcripts (Fig. 3). Although Acsl4 message did not change developmentally,
Acsl4 mRNA was abundant, representing 50% of total Acsl transcripts at all time points (Fig.
3). Message for Acsl5 and 6 together comprised less than 5% of total Acsl transcripts (Fig. 3).
Heart ACS activity is inhibited by triacsin C
To determine the contribution of the separate ACSL isoforms to the ACSL specific activity
measured, we used the inhibitors triacsin C and troglitazone. Triacsin C inhibits only ACSL
1, 3 and 4 [31,38] and thiazolidinediones inhibit only ACSL4 [31,38]. Incubating heart total
membranes with 10 μM triacsin C inhibited ACS activity measured with [14C]palmitate as
substrate 87 to 97% at all developmental time points (Fig. 4), suggesting that ACSL5 and
ACSL6, which are not inhibited by triacsin C, contribute minimally to heart ACS specific
activity. This result is consistent with our qRT-PCR analysis which showed that Acsl5 and 6
message levels were very low (Fig. 3). Contrary to the abundance of Acsl4 transcript, treatment
of heart membranes with 50 μM troglitazone inhibited ACSL activity less than 5%, indicating
that ACSL4 contributed very little to total heart ACSL activity (Fig. 4). It is unclear why
troglitazone appeared to increase ACSL specific activity 10–20% in the P18, P25 and adult
samples. Taken together, the mRNA expression data and inhibition studies strongly suggest
that ACSL3 may provide the majority of fetal and immediate postnatal ACSL activity and that
ACSL1 is the major contributor to postnatal and adult activity.
Arachidonate (20:4) inhibits the synthesis of palmitoyl-CoA in heart membranes from E16
Because a significant number of Acsl3 transcripts were most apparent at E16 and P1, we
assessed the relative contribution of the ACSL3 isoform to total ACSL specific activity. When
assayed with [14C]palmitate, purified ACSL4 is inhibited 50% by < 1 μM 20:4, whereas
arachidonate is a poor substrate for ACSL3 and 50 μM arachidonate is required to inhibit
ACSL3 50% [38]. Thus, one would expect competitive inhibition at low concentrations of 20:4
in membranes that contained relatively more ACSL4 activity, however, arachidonate had no
effect on palmitoyl-CoA synthetase activity in heart membranes from adult mice (Fig. 5). In
P1 samples, arachidonate inhibited ACSL activity a modest 13%. In E16 heart membranes,
arachidonate inhibited palmitoyl-CoA synthesis as much as 44%, but inhibition required high
concentrations of 20:4. Further, because troglitazone had little effect on ACSL activity (Fig.
de Jong et al. Page 5













4), the data suggest that ACSL3 is the major activity competed for by arachidonate on E16 and
that ACSL3 contributes considerably to the activation of long-chain fatty acids in the
embryonic heart.
Fetal heart phospholipids are enriched in myristate (14:0) and arachidonate (20:4)
Although each of the ACSL isoforms can use fatty acids of 12–22 carbons, the isoforms differ
in their preferred fatty acid substrates. Because ACSL3 displays the highest activity with laurate
(12:0), myristate (14:0), arachidonate (20:4), and eicosapentaenoic acid (20:5) [39], we
determined the FA composition of heart phospholipids to confirm that ACSL3 contributes
functionally to heart FA metabolism.
The most abundant fatty acids in adult heart phospholipids were 22:6, 18:0, 18:2, 16:0, 18:1,
20:4, and 22:5 (presented in descending order of abundance, Table 2), consistent with previous
reports [40]. In P1 hearts, however, the most prevalent fatty acids were 18:1>16:0>18:0,
18:2>20:4>22:6>22:5. In hearts from day 16 embryos, 16:0 was most abundant followed by
18:0, 20:4, 18:1, 18:2, 22:6, and 22:5. These differences in the distribution of fatty acids
between heart lipids isolated from the embryo and adult are consistent with the hypothesis that
different ACSL isoforms activate fatty acids for phospholipid synthesis during each of these
times, but may also reflect, in part, the availability of the different fatty acid species.
Of the major fatty acids, docosahexaenoic acid (22:6) was 3-fold higher in adult mouse heart
than in E16 and P1 (Table 2). High levels of 22:6 have been previously reported in rodent heart
and muscle phospholipids [40,41]. In other tissues, such as liver and adipose, 22:6 is a minor
constituent of membrane phospholipids [41,42]. Our data do not support a role for an ACSL
isoform in 22:6 metabolism because only the expression of Acsl1 transcripts is increased in the
adult, and ACSL1 does not thioesterify 22:6 efficiently [43]. Fatty acid transport proteins-1
and -6 are present in adult heart [29] and may contribute to increased 22:6 presence.
In contrast, arachidonic acid (20:4) was 2- to 2.4-fold higher in P1 and E16 heart lipids,
respectively, compared to adult (Fig. 6). Although all ACSL isoforms can activate 20:4, it is
a preferred fatty acid for ACSL3, 4, and 6 [20,38,39,43,44]. Unique to ACSL3 is its high
activity with 12- and 14-carbon fatty acid substrates [39]. To differentiate between
contributions from ACSL3, 4, and 6, we examined the prevalence of myristate (14:0) and 20:4
in E16, P1, and adult hearts. Interestingly, we observed that both 14:0 and 20:4 were 3-fold
higher in E16 heart phospholipids than in those from adult hearts (Fig. 6). These data are
consistent with the high expression levels of Acsl3 mRNA in the day 16 embryo, and suggest
that the ACSL3 isoform contributes to the unique fatty acid profile of embryonic heart lipids.
Discussion
Long-chain acyl-CoA synthetases are required to activate fatty acids before their entry into all
degradative or synthetic pathways with the exception of eicosanoid synthesis. Studies of the
five cloned ACSL isoforms in fibroblasts, liver cell lines, and neuronal cell lines, have
suggested that each ACSL isoform channels fatty acids toward separate metabolic fates.
Studies using triacsin C, a fungal derived competitive inhibitor of ACSL1, 3, and 4 [31,38],
showed that 5 μM triacsin C inhibited de novo synthesis of triacylglycerol 93% and
phospholipids 83% in human fibroblasts, but did not impair phospholipid reacylation [45]. In
primary rat hepatocytes triacsin C inhibited de novo TAG synthesis 73%, but inhibited β-
oxidation only 33% [46]. Similarly, troglitazone, an inhibitor of ACSL4 activity, decreased
the incorporation of oleate into triacylglycerol and oxidative products 50% and 20%,
respectively, but did not affect the incorporation of oleate into phospholipid [46,47]. Also in
hepatocytes, overexpression of ACSL1 increased oleate incorporation into diacylglycerol and
phospholipids, and decreased incorporation into cholesterol esters and secreted triacylglycerol
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[48]. In the rat hepatoma cell line McArdle –RH 7777, overexpression of ACSL5 increased
de novo synthesis of TAG, but did not alter fatty acid oxidation [49]. In addition, ACSL1
overexpression in PC12 neuronal cells increased the internalization of oleate by 55%, and
increased arachidonate and docosahexanoic acid uptake by 25% [50]. In contrast,
overexpression of ACSL6 increased internalization of oleate by 90%, arachidonate by 115%,
and docosahexanoic acid by 70% [50]. Taken together these data support the hypothesis that
ACSL isoforms are functionally distinct. Although all five ACSL isoforms are expressed in
the heart, little is known about their individual functional roles, so we examined Acsl mRNA
expression and activity in the developing mouse heart in order to determine the isoforms most
critical for FA oxidation.
During the development of the embryo to neonate to the 2-month old adult mouse, many
ontological changes occur. In heart, the most pronounced change is the switch in substrate for
ATP generation. The fetal heart uses lactate and glucose, but immediately after birth glycogen
and glucose oxidation provide ATP, and subsequently fatty acids provide the primary fuel
[2]. Concomitant with the substrate switch, the pathway of fatty acid oxidation is up-regulated
via PPARα. PPARα mRNA increases dramatically in mouse hearts on P1, as compared to
embryonic day 16.5 [10]. Transcript levels decrease on day 7, but in the adult equaled the
amount observed on day 1. The expression of the fatty acid oxidation enzymes MCAD and
CPT-1, followed a similar pattern.
We observed a 14-fold increase in ACSL specific activity between E16 and P1 and a further
5-fold increase in the 2 month old adult (Fig. 1). Of the five ACSL isoforms, only the transcripts
for Acsl1 increased after birth (Fig. 2A). Acsl1 mRNA increased 3.7-fold on P1 compared to
E16, and reached a maximal 5.5-fold increase on P18. This pattern of Acsl1 mRNA expression
matches the developmental pattern of expression observed for transcripts of Mcad and Aco
(Fig. 2C, D), genes required for fatty acid oxidation and regulated by PPARα [6–10]. The
Acsl1 promoter contains a PPAR response element [51,52], and Acsl1 transcript abundance is
diminished in the absence of PPARα [26,27]. A study of rat cardiomyocytes demonstrated that
fatty acid and PPARα agonists are able to upregulate Acsl1 [25]. Our data are consistent with
Acsl1 being a PPARα regulated gene during heart development. Because the expression of the
transcripts for the other Acsl isoforms decreased or remained unchanged after birth compared
to the fetus (Fig. 2B), it appears that transcription of Acsl3, 4, 5, and 6 is not up-regulated by
PPARα.
The increase in ACS specific activity we observed in developing mouse heart mirrored the
pattern observed for Acsl1 mRNA expression (Figs. 1 and 2A). However, the magnitude of the
increase in ACSL activity was 3.8-fold greater than the increase in Acsl1 mRNA. Discordance
between mRNA and protein has been previously reported for ACSL isoforms [24]. The post-
natal increase in heart ACSL activity is similar to the increase in post-natal palmitoyl-CoA
synthetase activity previously reported in both heart and liver [37]. Our studies with the
inhibitors triacsin C and troglitazone were consistent with ACSL1 being the predominant
isoform contributing to ACSL activity in postnatal heart (Fig. 4). Taken together, these data
lead us to conclude that after birth ACSL1 becomes the major isoform providing activated fatty
acids for oxidation.
Our results show that in the adult heart the number of Acsl3, 5, and 6 transcripts was low relative
to Acsl1 and 4 (Fig. 3), consistent with previous reports of Acsl expression in adult heart [24,
25]. Acsl3 transcripts were 16-fold more abundant at E16 than in the adult (Fig. 2 B). Although
ACSL activity was low on E16, arachidonate inhibited palmitoyl-CoA synthetase activity
(Fig. 5), indicating that the acyl-CoA synthetase(s) catalyzing the reaction preferred the
polyunsaturated fatty acid compared to 16:0. Both ACSL3 and ACSL4 prefer 20:4 over 16:0
[38], but because 50 μM troglitazone minimally inhibited ACSL activity at all developmental
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time points (Fig. 4), we concluded that ACSL4 did not contribute significantly to heart ACSL
activity.
We propose that ACSL3 plays a significant role in the embryonic heart. Phospholipids from
hearts on E16 are enriched in myristate and arachidonate (Fig. 6), fatty acids uniquely preferred
by ACSL3 [39], suggesting that ACSL3 contributes functionally to heart fatty acid metabolism
in the fetus. Strengthening the argument that ASCL3 is important for fetal heart development
are the presence of DNA motifs for the cardiogenic transcription factors, GATA and Nkx2.5,
in the 5′ flanking region of Acsl3 [53,54]. Although transactivation assays with the ACSL3 5′
flanking region demonstrated that the region containing the GATA and Nkx2.5 motifs contains
a negative promoter element [53], the cell line used did not express the cardiac GATA-4 and
Nkx2.5 transcription factors. Further studies on GATA-4 and Nkx2.5 regulation of ACSL3
transcription in rat heart will be needed to determine whether these transcription factors
contribute to high ACSL3 transcript levels in the embryo.
Although ACSL4 transcript is abundant in mouse heart (Fig. 3), we do not believe that ACSL4
contributes significantly to total ACSL activity because troglitazone, which inhibits only
ACSL4 [31,38], did not inhibit ACS specific activity at any developmental time point (Fig. 4).
ACSL4 may play a role in heart lipoprotein synthesis as has been proposed for ACSL4 in liver
[12,13,21,22]. Heart lipoprotein synthesis is increased under conditions of diabetes [55]. If
ACSL4 is important for lipoprotein assembly, we would expect ACSL4 to be up-regulated
under the same conditions.
In summary, our data support the hypothesis that each ACSL isoform has a specific role in the
channeling of fatty acids toward distinct metabolic fates. In addition, some of these roles may
be further modulated by subcellular location and/or tissue specificity. For example, we found
that the expression of ACSL1 mRNA and activity is increased concomitant with the
upregulation of the FA oxidation program, suggesting that ACSL1 is the major isoform
responsible for activating long-chain fatty acids for myocardial β-oxidation after birth. This
result is in contrast to the function of ACSL1 in liver, where overexpression of ACSL1 in
hepatocytes does not alter oleate incorporation in β-oxidation products, but does increase oleate
incorporation into diacylglycerol and phospholipids [48]. Further studies of the function of
ACSL isoforms in different tissues will be needed to complete our understanding of the
functional role of ACSL in various fatty acid utilizing pathways.
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Figure 1. Heart ACSL activity increased after birth
Total membrane protein from hearts at embryonic day 16 (E16), postnatal days 1, 7, 18, 25,
and adult were assayed for ACSL activity with [14C]palmitate as substrate as described in
Materials and Methods. n = 3 for each time point. * indicates P ≤ 0.0002 vs. E16. # indicates
P ≤ 0.02 vs. P1.
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Figure 2. Heart Acsl1 mRNA increased after birth
The level of the transcript for each Acsl isoform was determined by qRT-PCR as described in
Materials and Methods. The expression of each isoform is presented as the 2-log ratio to Gapdh
relative to E16. (A) Acsl1, * indicates P ≤ 0.007 vs. E16 (B) Acsl3, * indicates P ≤ 0.03 vs.
E16; (C) Mcad, * indicates P ≤ 0.01 vs. E16; (D) Aco, * indicates P ≤ 0.009 vs. E16; n = 4 for
each time point and each gene. Some error bars for standard deviation are within in the symbol.
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Figure 3. Acsl3 and 4 transcripts are most abundant in the fetal heart, while Acsl1 and 4 are most
abundant in the adult
The percent of Acsl1, 3, 4, 5, and 6 mRNAs as a percent of total Acsl transcripts was determined
as described in Materials and Methods.
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Figure 4. Triacsin C inhibited ACSL activity at all developmental time points
Total membrane protein from hearts at embryonic day 16 (E16) and postnatal days 1, 7, 18,
25, and adult were assayed for ACSL activity in the presence of 10 μM triacsin C (❏) or 50
μM troglitazone (■) as described in Materials and Methods. Data are presented as a percent of
control ACSL activity assayed in the presence of DMSO. n = 3 for each time point.
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Figure 5. Arachidonic acid inhibited palmitoyl-synthase activity at embryonic day 16
Total membrane protein from hearts at embryonic day 16 (♦), postnatal day 1 (■), and adult
(●) were assayed for [14C]palmitoyl synthase activity in the presence of increasing
concentrations of arachidonic acid (20:4) as described in Materials and Methods. Data are
presented as the percent of ACS activity at 0 μM 20:4. n = 3 for each point. Some error bars
for standard deviation are within the symbol. * indicates P ≤ 0.05 vs. 0 μM 20:4. # indicates
P ≤ 0.04 vs. adult.
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Figure 6. Phospholipids were enriched in myristate and arachidonate at embryonic day 16
The fatty acid composition of total phospholipids from hearts at embryonic day 16 (E16 ❏),
postnatal day 1 ( ), and adult (■) was determined as described in Materials and Methods. For
E16 and P1, the value presented is an average of a pool of 8–10 hearts. n = 3 for the adult.
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Table I
Primer and probe sequences used for qRT-PCR.
position accession #
Acsl1 forward GCAAGAACAGCTGAAGCCC 1573a BC056644
reverse AGGTGCCATTTGGCAGCCA 1651a
probe CCAATGTCCCCCGTGTGTAACCA 1606a
Acsl 3 forward CAATTACAGAAGTGTGGGACT 1454a NM_028817.2
reverse CACCTTCCTCCCAGTTCTTT 1543a
probe TACCGGCAGAGTGGGAGCACCA 1479a
Acsl 4 forward TATGGGCTGACAGAATCATG 1396a NM_207625
reverse CAACTCTTCCAGTAGTGTAG 1465a
probe TAACTTCAGTAACTGTTCCAGCACC 1417a
Acsl 5 forward GGCCAAACAGAATGCACAG 1330a NM_027976
reverse GGAGTCCCAACATGACCTG 1403a
probe TGTCCAGTCCCCAGGTGATGTAA 1361a
Acsl 6 forward TGAATGCACAGCTGGGTGTA 1383a AY786363
reverse ATGTGGTTGCAGGGCAGAG 1466a
probe TGTCCAGTCCCCTGGCGTTGTGA 1406a
Aco forward CAAGGAAGTGGCGTGGAACT 1533a BC054727
reverse CTGCAAAGACCTTAACGGTC 1602a
probe ACTTCTGTCGACCTTGTTCGCGCAA 1555a
Mcad forward GAGCAGGTTTCAAGATCGCA 800a BC013498
reverse ACTTCGTGGCTTCGTCTAGA 904a
probe CTAGCCCGACAGCGCCAGCT 855a




Position relative to translation start for indicated accession number
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Table II
Fatty acid composition of heart phospholipids
Fatty Acid E16 P1 Adult
14:0 0.91 0.59 0.27± 0.08
14:1 0.00 0.04 0.02 ± 0.02
16:0 23.12 17.96 13.90 ± 0.99
16:1 2.07 1.43 0.46 ± 0.06
18:0 16.10 13.11 17.94 ± 0.27
18:1 14.93 23.54 9.68 ± 0.44
18:2 10.91 12.17 14.94 ± 1.24
20:0 0.46 0.43 0.27 ± 0.17
18:3 0.25 0.20 0.12 ± 0.01
20:1 0.19 0.2 6 0.36 ± 0.01
20:2 1.04 1.09 0.60 ± 0.06
20:3 1.15 0.99 0.67 ± 0.11
20:4 15.84 10.07 6.70 ± 0.19
20:3 0.63 0.47 0.08 ± 0.14
22:0 0.48 0.64 0.03 ± 0.05
22:1 0.58 0.35 0.25 ± 0.04
20:5 0.15 0.08 0.30 ± 0.07
24:0 0.15 0.14 0.00 ± 0.01
24:1 0.09 0.04 0.07 ± 0.01
22:5 1.99 2.77 1.71 ± 0.14
22:6 8.95 9.02 31.63 ± 3.29
Heart lipids were extracted and fatty acid composition was determined as described in Materials and Methods. Data are presented as percent of total fatty
acids recovered. For E16 and P1, the values presented are an average from a pool of 8–10 hearts. For the adult, n=3.
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